A Phase 3 Randomized Comparator-Controlled Clinical Trial to

Recruiting

99 years or below

All

Phase 3

1 Location

Brief description of study

This study will involve patients with high risk non-muscle invasive bladder cancer (NMIBC) that is persistent (cancer stays) or recurrent (cancer comes back) following Bacillus Calmette-Guérin BCG treatment. The purpose of this study is to: o Test the safety of the study drugs, pembrolizumab in combination with Bacillus Calmette-Guerin (BCG) o See how your body handles pembrolizumab and BCG o See how well pembrolizumab in combination with BCG works compared to BCG alone o See if pembrolizumab helps patients getting BCG have a better quality of life o See if pembrolizumab helps patients getting BCG live longer Pembrolizumab has been approved FDA-approved for use for patients with certain types of bladder cancer; however, it has not yet been approved for your type of bladder cancer. Therefore, for your type of bladder cancer it is considered experimental. BCG is a live, but weakened, bacterial preparation that has been FDA-approved for use approved for patients with your type of bladder cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: TBD
Age: 99 years or below
Gender: All

Updated on 13 Feb 2019. Study ID: 832206

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).